10-Q: Soligenix Q2 2025: Net Loss Widens, Going Concern Doubt

Soligenix, Inc. reported a significant increase in net loss for Q2 2025, raising substantial doubt about its ability to continue as a going concern despite ongoing clinical trial progress.

Summary

• Net loss for the three months ended June 30, 2025, increased to $2,701,976, compared to $1,644,502 for the same period in 2024.
• Net loss for the six months ended June 30, 2025, increased to $5,653,244, compared to $3,559,829 for the same period in 2024.
• Cash and cash equivalents decreased to $5,097,670 as of June 30, 2025, from $7,819,514 as of December 31, 2024.
• Working capital decreased to $1,691,345 as of June 30, 2025, from $3,980,218 as of December 31, 2024.
• Research and development expenses significantly increased to $1,677,014 for Q2 2025 (from $501,158 in Q2 2024) and to $3,618,694 for the six months (from $1,596,198 in 2024), primarily due to costs for the Phase 2 BD study and the confirmatory Phase 3 CTCL trial, as well as third-party manufacturing.
• General and administrative expenses decreased slightly to $1,086,865 for Q2 2025 (from $1,243,517 in Q2 2024) and to $2,171,693 for the six months (from $2,265,568 in 2024).
• The company fully repaid all outstanding obligations and terminated its $20 million convertible debt agreement with Pontifax in February 2025.
• Patient enrollment for the confirmatory Phase 3 FLASH2 study of HyBryte in CTCL began in December 2024, with top-line results anticipated in the second half of 2026.
• Positive interim results from an ongoing open-label investigator-initiated study (IIS) of extended HyBryte treatment for CTCL showed 75% of patients achieved 'Treatment Success' after 18 weeks.
• The transfer and optimization of synthetic hypericin active ingredient manufacturing process with Sterling Pharma Solutions was successfully completed in July 2025.
• The Phase 2a proof-of-concept study for SGX945 (dusquetide) in Behcet's Disease (BD) was completed in July 2025, demonstrating biological efficacy.
• Richard Straube, MD, retired as Chief Medical Officer and Senior Vice President, effective August 12, 2025, and entered into a one-year consulting agreement as Consulting Chief Medical Officer.

Sentiment

Score: 3

Explanation: The company faces substantial doubt about its ability to continue as a going concern due to increasing losses and declining cash. While there is clinical progress with HyBryte and SGX945, and debt repayment is positive, the overall financial health is precarious, necessitating urgent capital raises and indicating high operational risk.

Positives

• Patient enrollment for the confirmatory Phase 3 FLASH2 study of HyBryte in CTCL commenced in December 2024, with top-line results expected in the second half of 2026.
• Positive interim results from an investigator-initiated study (IIS) of extended HyBryte treatment for CTCL showed 75% of patients achieved 'Treatment Success' after 18 weeks, reinforcing its potential as a safe and fast-acting therapy.
• Successfully completed the transfer and optimization of synthetic hypericin active ingredient manufacturing process with Sterling Pharma Solutions in July 2025, enabling cGMP for clinical trials and commercial manufacturing.
• Completed the Phase 2a proof-of-concept study for SGX945 (dusquetide) in Behcet's Disease (BD) in July 2025, demonstrating biological efficacy.
• Full repayment and termination of the $20 million convertible debt agreement with Pontifax in February 2025, eliminating associated interest expenses and liens.
• Interest income, net, increased to $69,823 for the three months and $145,851 for the six months ended June 30, 2025, primarily due to reduced interest expense from debt repayment.

Negatives

• Net loss significantly increased to $2,701,976 for the three months ended June 30, 2025, compared to $1,644,502 for the same period in 2024.
• Net loss for the six months ended June 30, 2025, increased to $5,653,244 compared to $3,559,829 for the same period in 2024.
• Cash and cash equivalents decreased by $2,721,844 to $5,097,670 as of June 30, 2025, from $7,819,514 as of December 31, 2024.
• Working capital decreased by $2,288,873 to $1,691,345 as of June 30, 2025, from $3,980,218 as of December 31, 2024.
• Management has substantial doubt about the company's ability to continue as a going concern beyond the first quarter of 2026 without securing additional financing.
• No revenue was generated for the three and six months ended June 30, 2025, compared to $2,342 and $119,371 respectively in the prior year periods.
• The company sold the remaining capacity of its At-The-Market (ATM) facility as of July 1, 2025, indicating a depleted immediate source of equity financing.
• The FDA expressed a preference for a longer duration comparative study over a placebo-controlled trial for HyBryte in CTCL, potentially complicating U.S. regulatory approval.
• A second Phase 3 clinical trial for SGX942 (dusquetide) in oral mucositis is required to support marketing authorization, and continued development is contingent upon identifying a potential partner.

Risks

• Uncertainty as to whether product candidates will be sufficiently safe and effective to support regulatory approvals.
• Inherent uncertainty in developing therapeutics and vaccines, and manufacturing and conducting preclinical and clinical trials.
• Ability to obtain future financing or funds when needed, either through capital raises, indebtedness, or strategic financing/commercialization partnerships.
• Ability to secure government grants or contracts to support vaccine development.
• Ability to maintain listing on The Nasdaq Capital Market and meet its listing requirements.
• Product development and commercialization efforts may be reduced or discontinued due to difficulties or delays in clinical trials or a lack of progress or positive results from research and development efforts.
• The possibility that products under development may not gain market acceptance.
• Expected revenues (including sales, milestone payments, and royalty revenues) from product candidates and any related commercial agreements may not be realized.
• The ability of manufacturing partners to supply clinical or commercial products in a safe, timely, and regulatory compliant manner.
• Competition existing today or that may arise in the future, including the possibility that others may develop technologies or products superior to current products.
• The effect that global pathogens (e.g., COVID-19) could have on financial markets, materials sourcing, service providers, patients, clinical study sites, governments, and population.
• Shareholders may suffer substantial dilution related to issued pre-funded warrants, common stock warrants, options, and future equity issuances.
• Macroeconomic and geopolitical uncertainties may further restrict access to capital, exacerbating liquidity challenges.
• Concerns regarding the company's ability to continue as a going concern could negatively impact relationships with business partners, vendors, and other stakeholders.
• No assurance that the company will obtain additional governmental grant funding.
• No assurance that the company can consummate potential partnerships, merger/acquisition strategies, or additional equity/royalty/debt financing at favorable pricing.

Future Outlook

The company anticipates top-line results for the Phase 3 FLASH2 study of HyBryte in CTCL in the second half of 2026. It plans to continue discussions with the FDA on potential modifications to the development path for HyBryte. The company will continue to apply for additional government funding for its programs, pursue potential partnerships for pipeline programs, explore merger and acquisition strategies, and evaluate additional equity/royalty/debt financing opportunities. It expects to continue generating losses in the foreseeable future and believes it has sufficient resources to support development activities and meet obligations through the first quarter of 2026.

Management Comments

• Management believes that the Company has sufficient resources to support development activities, business operations, and meet its obligations through the first quarter of 2026.
• However, as of the date of filing this Quarterly Report on Form 10-Q, the Company does not have sufficient cash and cash equivalents to fund operations for at least 12 months following the issuance of these financial statements. These factors raise substantial doubt about the Company’s ability to continue as a going concern.
• To alleviate the conditions that raise substantial doubt about the Company’s ability to continue as a going concern, the Company’s plans, as of June 30, 2025, include securing: additional capital, potentially through a combination of public or private equity offerings and strategic transactions, including potential alliances and drug product collaborations; additional proceeds from government contract and grant programs; additional proceeds from the sale of shares of the Company’s common stock via the At Market Issuance Sales Agreement.
• There is no assurance that the Company will be successful in securing sufficient financing on acceptable terms, if at all, to continue operations, enter into strategic transactions that provide the necessary capital, or implement other strategies to mitigate the substantial doubt about its ability to continue as a going concern.
• Failure to obtain adequate capital when needed may force the Company to delay, reduce, or eliminate business development efforts, negatively impacting its ability to achieve its objectives, remain competitive, and maintain its financial condition and operating results.
• We will continue to use equity instruments to provide a portion of the compensation due to vendors and collaboration partners and expect to continue to do so for the foreseeable future.
• We plan to pursue potential partnerships for pipeline programs as well as continue to explore merger and acquisition strategies.

Industry Context

Soligenix operates in the highly competitive and capital-intensive biopharmaceutical industry, focusing on rare diseases and public health solutions. Its strategy of seeking Orphan Drug and Fast Track designations aligns with industry trends to accelerate development for unmet medical needs. The reliance on government grants for its Public Health Solutions segment is typical for biodefense and infectious disease programs. The challenges in securing FDA approval for HyBryte, despite EMA agreement, highlight the stringent and often divergent regulatory pathways in different regions. The continuous need for capital raises is common for clinical-stage biotech companies with no commercial products, especially those with a significant burn rate and no immediate revenue streams.

Comparison to Industry Standards

• HyBryte (CTCL) has achieved Orphan Drug and Fast Track designations from the FDA, and Orphan Drug, Promising Innovative Medicine (PIM), and Innovation Passport from the EMA/MHRA, which are strong indicators of recognition for unmet medical need and potential for expedited regulatory review, aligning with industry best practices for rare disease development.
• SGX942 (Oral Mucositis) received Fast Track designation from the FDA and PIM designation from the MHRA, similar to HyBryte, suggesting a recognized need for new therapies in this area. However, the requirement for a second Phase 3 trial and a partner after the first Phase 3 failed its primary endpoint (despite showing biological activity) indicates challenges in meeting rigorous statistical significance benchmarks, which is a common hurdle in drug development.
• SGX945 (Behcet's Disease) received Fast Track designation from the FDA, reflecting efforts to accelerate development for rare diseases, consistent with industry trends.
• RiVax (Ricin Toxin Vaccine) has been granted Orphan Drug and Fast Track designations by the FDA and Orphan Drug by the EMA, underscoring its importance as a biodefense countermeasure. The potential for a biodefense Priority Review Voucher (PRV) is a significant incentive in this niche, offering a valuable asset upon approval.
• The company's ongoing need for capital and 'going concern' doubt is a common challenge for small, clinical-stage biotechs that are pre-revenue, but it represents a critical financial risk that deviates significantly from the financial stability seen in more mature, revenue-generating pharmaceutical companies.

Management Changes

Corporate Governance

Legal Proceedings

• The company is a party to claims and legal proceedings arising in the ordinary course of business, with management evaluating exposure and allocating monies for potential losses if estimable and probable. No specific new material proceedings were detailed in the filing.

Related Party Transactions

• Amendment to Dr. Schaber's employment agreement in May 2025 to increase the number of shares of common stock issuable to him from 2,084 to 200,000 immediately prior to the completion of certain strategic transactions (e.g., change of control).

Stakeholder Impact

• Shareholders face significant dilution risk from past and future equity issuances, and potential for further share price decline due to the 'going concern' doubt and continuous need for capital.
• Employees may experience uncertainty due to the company's precarious financial position, although ongoing R&D activities suggest continued operations.
• Business partners and vendors could be negatively impacted by concerns regarding the company's ability to continue as a going concern, potentially affecting future collaborations or payment terms.
• Creditors have seen a reduction in immediate risk due to the full repayment of the convertible debt, but the overall financial health remains a concern for any future debt financing.
• Patients involved in clinical trials for rare diseases (CTCL, BD) and those awaiting biodefense vaccines (Ricin, Ebola, Marburg) may benefit from continued product development, but the company's financial instability poses a risk to the long-term continuity of these programs.

Next Steps

• Continue enrollment and execution of the FLASH2 study for HyBryte in CTCL.
• Continue discussions with the FDA on potential modifications to the development path for HyBryte to adequately address their feedback.
• Expand development of synthetic hypericin (SGX302) into psoriasis with the conduct of a Phase 2a clinical trial.
• Design a second Phase 3 clinical trial for SGX942 (dusquetide) in oral mucositis and attempt to identify a potential partner(s) to continue this development program.
• Expand development of dusquetide (SGX945) into Behcet's Disease by conducting a Phase 2a clinical trial.
• Continue development of the ThermoVax platform technology in combination with programs for RiVax and filovirus vaccines, with U.S. government or non-governmental organization funding support.
• Continue to apply for and secure additional government funding for Specialized BioTherapeutics and Public Health Solutions programs through grants, contracts, and/or procurements.
• Pursue business development opportunities for pipeline programs and explore all strategic alternatives, including merger/acquisition strategies.
• Acquire or in-license new clinical-stage compounds for development, as well as evaluate new indications with existing pipeline compounds.
• Submit additional contract and grant applications for further support of programs.
• Continue to use equity instruments to provide a portion of the compensation due to vendors and collaboration partners.
• Continue to pursue Net Operating Loss (NOL) sales in the state of New Jersey, if the program remains available.
• Conduct one interim analysis for the FLASH2 study when approximately 60% of the total subjects have completed the primary endpoint evaluation.

Key Dates

Recommendation

The company's financial position is highly precarious, with management explicitly stating 'substantial doubt about its ability to continue as a going concern' beyond Q1 2026. This is driven by significantly increasing net losses, declining cash and working capital, and a lack of revenue. While there is clinical progress with HyBryte and SGX945, and debt repayment is positive, the continuous need for dilutive capital raises (with the ATM facility now exhausted) presents extreme risks. The FDA's preference for a different study design for HyBryte in the US adds regulatory complexity and uncertainty. These factors collectively point to a high-risk investment with a strong likelihood of further value erosion, making it a strong sell for seasoned investors.

Keywords

Soligenix, SNGX, Biopharmaceutical, Rare Diseases, CTCL, HyBryte, SGX301, Synthetic Hypericin, FLASH2, Psoriasis, SGX302, Dusquetide, SGX942, Oral Mucositis, Behcet's Disease, SGX945, RiVax, ThermoVax, Vaccines, Ricin Toxin, Ebola, Marburg, COVID-19, SEC Filing, 10-Q, Clinical Trials, Biotech, Orphan Drug, Fast Track, Going Concern, Capital Raise